Data protection Impressum

Pharma

AC Immune’s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

AC Immune receives FDA Fast Track designation for Alzheimer’s disease therapy

6 August 2024

Biopôle is joining forces with Swiss Healthcare Startups to extend the Vanguard accelerator to digital health start-ups in German-speaking Switzerland, while also welcoming Hôpital de La Tour to its Corporate Partnership Programme.

Biopôle expands its accelerator program and welcomes new corporate partner

5 August 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (July 2024)

17 July 2024

Asceneuron has secured USD 100 million in Series C funding to advance its mission of developing OGA inhibitors for neurodegenerative diseases like Alzheimer's.

Asceneuron raises USD 100 million to advance Alzheimer’s treatment

16 July 2024

Global demand for biologics is at an all-time high, and Western Switzerland is positioning itself as a key player in meeting that demand.

Biomanufacturing in Western Switzerland

BioAlps, the life sciences cluster of Western Switzerland, offers a dynamic network, an innovative and supportive environment and direct access to the region's vibrant life sciences ecosystem.

Why Switzerland

BioAlps, Western Switzerland’s life sciences cluster

Vaud-based life sciences company Limula has secured CHF 6.2 million to democratize access to life-saving cell and gene therapies.

Limula secures CHF 6.2 million to advance automated cell therapy platform

21 May 2024

Takeda will receive an exclusive option to license AC Immune's ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer's disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.

AC Immune and Takeda sign USD 100 million deal to treat Alzheimer’s disease

13 May 2024

Ikerian AG, along with its subsidiary RetinAI, has successfully completed a USD 6.18 million Series A extension financing round to propel the development and commercial rollout of innovative medical technologies.

Ikerian, parent company of RetinAI, secures USD 6.18 million for AI-driven medical advancements

13 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

1 2 3 4 5 6 7 8 9 … 15